

## OPTICALLY ACTIVE NAPROXEN BY KINETIC RESOLUTION

Amelie FRANCK and Christoph RÜCHARDT\*

Chemisches Laboratorium der Universität Freiburg,  
Albertstr. 21, D-7800 Freiburg, BRD

Optically active naproxen is prepared from its racemic precursor by kinetic resolution via the anhydride and its reaction with optically active 1-(4-pyridyl)ethanol in high chemical and optical yield.

Several  $\alpha$ -arylalkanoic acids are clinically used as nonsteroidal antiinflammatory agents (antiphlogistica).<sup>1)</sup> Frequently one enantiomer exceeds the other in activity<sup>1a)</sup> as it is the case for naproxen 3, one of the most potent and best tolerated pharmaceuticals of this family. The S(+) enantiomer exceeds the R(-) enantiomer by a factor 28 in activity.<sup>1a,2)</sup> The present interest in this drug is particularly evident from a series of new procedures for naproxen syntheses in the recent literature, mainly in the patent literature<sup>2,3)</sup> and from several patents dealing with ways for separating the antipodes.<sup>2,4)</sup>

Our attempts to obtain optically active naproxen 3 by an asymmetric synthesis<sup>5)</sup> via the reaction of 6-methoxy-2-naphtyl-methyl ketene with optically active  $\alpha$ -phenylethanol in the presence of a tertiary amine base were only partly successful.<sup>6)</sup> This was probably due to insufficient persistence of the ketene and to difficulties with ester hydrolysis without racemisation.

We are reporting now a successful stereospecific synthesis of optically active naproxen 3 from its racemic precursor by a method recently developed for the synthesis of pyrethroid acids.<sup>7)</sup>




Table 1. Reaction of 2-(6-Methoxy-2-naphthyl)-propanoic Anhydride 1 and 1-(4-Pyridyl) ethanol 2 in a 1:1 molar ratio at 25°C

No.	<u>1</u> (mmol)	Solvent (ml a))	<u>2</u>	<u>3</u> Yield/% b) ± 2%	<u>3</u> e.e. c) ± 2%	<u>4</u> Yield/% b) ± 2%	<u>4</u> d.e. d) ± 2%
1	1.1	20T/26E	rac.	e)	-	48	64 f)
2	1.1	40T/3E	rac.	e)	-	46	72 f)
3	1.1	40T/3E	(-)S g)	70	54 h)	58	60 i)
4	2.3	80T/5E	(+)-R k)	81	55 l)	55	74 m)

a) T = toluene, E = ether. b) Isolated yields.

c) Corrected for incomplete o.p. of 2. d) Analyzed by HPLC and in No. 1-2 by NMR; the d.e. values are not corrected for incomplete o.p. of 2 because racemic 2 induces even somewhat higher d.e.'s than optical active 2. 7.,8)

e) Not analyzed. f) Excess R,R and S,S-diastereomer.

g) o.p. = 95%. h) Corrected for, g) excess (-)R enantiomer.

i) Excess S,S over R,S. diastereomer. k) o.p. = 89%.

l) Corrected for, k) excess (+)S enantiomer.

m) Excess R,R over S,R-diastereomer.

Racemic 2-(6-methoxy-2-naphthyl)propanoic acid<sup>2,3)</sup> was transformed to the diastereomeric mixture of it's anhydride by treatment with acetic anhydride.<sup>7)</sup> On reaction of 1 with an equimolar amount of optically active 1-(4-pyridyl)ethanol 2 naproxen 3 is obtained in 70-80% chemical yield and more than 50% optical yield. The second product, the ester 4 is isolated in more than 50% yield and 60-70% optical yield. As discussed previously this high asymmetric induction is due to kinetic resolution.<sup>7)</sup> Correspondingly therefore one pair of diastereomers of 4 is obtained with high stereoselectivity from racemic 2.<sup>8)</sup> The results recorded in Table 1 have not yet been optimized. 3 was obtained from 4 by acid hydrolysis in aqueous dioxane in 85% chemical yield without racemisation.<sup>9)</sup> Because optically active 2 has been recovered from similar hydrolysis reactions<sup>7)</sup> and because racemic 1 should be obtained, when R(-)-3 is treated with acetic anhydride and pyridine<sup>7)</sup> this reaction sequence should be suited for the complete conversion of racemic -3 into S(+)-3, the pharmaceutically active naproxen.

*Support of this work by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie is gratefully acknowledged.*

#### References

- 1 a) T.Y. Shen, *Angew. Chem.*, 84, 512 (1972); *Angew. Chem., Int. Ed. Engl.*, 11, 460 (1972); b) M. Kuchar, B. Brunova, V. Rejholec, Z. Roubal and O. Nemecek, *Collect. Czech. Chem. Commun.*, 46, 1173 (1981); c) K. Hino, H. Nakamura, Y. Nagaj, H. Uno, and H. Nishimura, *J. Med. Chem.*, 26, 277 (1983) and references cited therein.
- 2) I.T. Harrison, B. Lewis, O. Nelson, W. Rocks, A. Roszkowski, A. Tomalonis, and J.H. Fried, *J. Med. Chem.*, 13, 203 (1970); G. Tsuchihashi, *Tetrahedron Lett.*, 1982, 5427.
- 3) C. Giordano, G. Castaldi, F. Casagrande, and A. Belli, *J. Chem. Soc., Perkin, Trans. 1*, 1982, 2575; C. Giordano, G. Castaldi, F. Casagrande, and L. Abis, *Tetrahedron Lett.*, 1982, 1385; C. Graziano, A. Belli, F. Uggeri, and C. Giordano, *J. Org. Chem.*, 48, 4658 (1983); H. Kyowa (Kogoco), JP 58 21, 644 (8.2.1983); *Chem. Abstr.*, 98, 215332 (1983); G.C. Schloemer (Syntex), EP 64, 394 (10.11.1982); *Chem. Abstr.*, 98, 143130 (1983). G. Tsuchihashi, S. Mitamura, and K. Kitajima (Sagami Chem. Res. Cent.), EP 48, 136 (24.3.1982); *Chem. Abstr.*, 97, 162599 (1982); K. Arai, Y. Ohara, T. Iizumi, and Y. Takakuwa (Nissan Chem. Ind.), *Tetrahedron Lett.*, 1983, 1537; G.J. Mathews, and R.A. Arnold (Syntex), Can. Ca 1 115 722 (5.1.1982); *Chem. Abstr.*, 97, 109 699 (1982); W. Buchowieski, S. Cachula, S. Kotlicki, H. Zajac, and J. Zicwiona, Pol. PL 114, 148 (24.2.1977); *Chem. Abstr.*, 98, 53447 (1983); T. Amano, K. Yoshikawa, T. Sano, Y. Ohuchi, M. Ishiguro, M. Shiono, Y. Fujita, and T. Mishida, EP 74, 008 (16.3.1983); *Chem. Abstr.*, 99, 69707 (1983); A. Gardano, F. Francalanci, and M. Fog (Montedison), EP 76, 722 (19.4.1983); *Chem. Abstr.*, 99, 70391 (1983); Laboratories Bago Belg. BE 890, 221 (4.9.1981); *Chem. Abstr.*, 96, 199349 (1982); Y. Tamura, Y. Shirouchi, and J. Haruta, *Synthesis*, 1984, 181.
- 4) Blasinachim, JP 5800, 933 (6.1.1983); *Chem. Abstr.*, 98, 160466 (1983); Nissan Chem., Ind. JP 57, 171, 938 (22.10.1982); *Chem. Abstr.*, 98, 160461 (1983); V. Cannata, and G. Tamerlani (Alfa Chem. Italiana), DE 3 212 170 (21.10.82); *Chem. Abstr.*, 98, 53448 (1983); H. Nohira, JP 8207, 440 (14.1.1982); *Chem. Abstr.*, 93, 186042 (1980).
- 5) J. Jähme and C. Rüchardt, *Angew. Chem.*, 93, 919 (1981); *Angew. Chem., Int. Ed. Engl.*, 20, 885 (1981). U. Salz and C. Rüchardt, *Tetrahedron Lett.*, 1982, 4017; C. Rüchardt, J. Jähme, and U. Salz, DE-OS 31 16 474 (25.4.1981).
- 6) Dissertation J. Jähme, Universität Freiburg, 1982.

- 7) H. Gärtner, U. Salz, and C. Rüchardt, *Angew. Chem.*, 96, 166 (1984); *Angew. Chem., Int. Ed. Engl.*, 23, 162 (1984); U. Salz and C. Rüchardt, *Chem. Ber.* in print; C. Rüchardt, A. Franck, H. Gärtner, U. Salz, and K. Schickinger, DP applied (5.8.1983).
- 8) A. Horeau, "Stereochemistry, Fundamentals and Methods," ed by H.B. Kagan, (1977), Vol. 3, p. 52.
- 9) Merck ion-exchanger I, 13 h, 90 °C; mp (3): 140-143 °C;  $[\alpha]_{D}^{22} = -34.7^{\circ}$  (c 1.0,  $\text{CHCl}_3$ ) 60% overall o.y.

(Received April 9, 1984)